Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2025 17:00 ET | Source: INVENTIVA

Inventiva annonce la fin du recrutement de l’étude clinique de Phase 3 NATiV3 évaluant lanifibranor chez les patients atteints de MASH et de fibrose avancée

Objectifs de recrutement dépassés avec 1.009 patients randomisés dans la cohorte principale et 411 dans la cohorte exploratoirePrincipaux résultats de NATiV3 attendus au deuxième semestre 2026 et, si...
March 26, 2025 16:00 ET | Source: INVENTIVA

Inventiva reports its 2024 full year results and provides a business update

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First tranche of up to €348 million Structured Financing closed with aggregate...
March 25, 2025 03:00 ET | Source: Middlefield Canadian Income PCC

Middlefield Canadian Income PCC - Annual Financial Report

Middlefield Canadian Income PCC (the "Company") Including Middlefield Canadian Income – GBP PC (the “Fund”), a cell of the Company Registered No: 93546 Legal Entity Identifier:...
March 21, 2025 06:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED’s fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March ...
March 19, 2025 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address...
March 18, 2025 20:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) and Innovent Biologics, Inc. (“Innovent”) (HKEX:...
March 18, 2025 14:25 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics to Highlight Lead Product Gelsolin’s Critical Role in Immune Function at Upcoming Conferences

Phase 2 clinical trial will be presented at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) conference in Brussels, Belgium on March 19, 2025. COO Valerie Ceva will...
March 12, 2025 17:19 ET | Source: Southern Energy Corp.

Southern Energy Announces Financings to Ramp Up Liquids-Rich Gas Production Across High Quality Gulf Coast Assets, Feeding a Growing Demand for U.S. Natural Gas at Premium Pricing

THIS ANNOUNCEMENT (THE “ANNOUNCEMENT”), INCLUDING THE APPENDIX TO THIS ANNOUNCEMENT (THE “APPENDIX”), AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR...
March 05, 2025 05:00 ET | Source: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Wong Tak...
March 03, 2025 01:30 ET | Source: Exosens

Exosens delivers very strong full-year 2024 results, overperforming on its IPO guidance; Sustained growth dynamic anticipated for 2025-2026

EXOSENS DELIVERS VERY STRONG FULL-YEAR 2024 RESULTS, OVERPERFORMING ON ITS IPO GUIDANCE SUSTAINED GROWTH DYNAMIC ANTICIPATED FOR 2025-2026 FY 2024 HIGHLIGHTS Strong revenue growth of +35.0%, above...